Literature DB >> 22571169

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

Dennis M Black1, Douglas C Bauer, Ann V Schwartz, Steven R Cummings, Clifford J Rosen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22571169      PMCID： PMC4015798          DOI： 10.1056/NEJMp1202623

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

2.  Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.

Authors:  Ann V Schwartz; Douglas C Bauer; Steven R Cummings; Jane A Cauley; Kristine E Ensrud; Lisa Palermo; Robert B Wallace; Marc C Hochberg; Adrianne C Feldstein; Antonio Lombardi; Dennis M Black
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

3.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741
  3 in total
  74 in total

1.  Duration of anti-resorptive therapy for osteoporosis.

Authors:  Robert A Adler
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

Review 2.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

3.  Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture.

Authors:  Sam Y Jiang; David J Kaufman; Bonnie Y Chien; Michael Longoria; Ross Shachter; Julius A Bishop
Journal:  Clin Orthop Relat Res       Date:  2019-03       Impact factor: 4.176

Review 4.  Osteoporosis Treatment: When to Discontinue and When to Re-start.

Authors:  Silvano Adami; Luca Idolazzi; Elena Fracassi; Davide Gatti; Maurizio Rossini
Journal:  Bone Res       Date:  2013-12-31       Impact factor: 13.567

5.  Bone alterations associated with HIV.

Authors:  Amy H Warriner; Michael Mugavero; E Turner Overton
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

6.  Effect of self-referral on bone mineral density testing and osteoporosis treatment.

Authors:  Amy H Warriner; Ryan C Outman; Adrianne C Feldstein; Douglas W Roblin; Jeroan J Allison; Jeffrey R Curtis; David T Redden; Mary M Rix; Brandi E Robinson; Ana G Rosales; Monika M Safford; Kenneth G Saag
Journal:  Med Care       Date:  2014-08       Impact factor: 2.983

7.  Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.

Authors:  Rebecca S Hayden; Moritz Vollrath; David L Kaplan
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

Review 8.  Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Authors:  Amy H Warriner; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 9.  Optimising the management of osteoporosis.

Authors:  Ziad Farrah; Ali Sm Jawad
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

10.  Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.

Authors:  Satoshi Soen; Takashi Umemura; Tsuyoshi Ando; Toshiaki Kamisaki; Masahiko Nishikawa; Ryoichi Muraoka; Yoshinori Ikeda; Kyoko Takeda; Mitsuharu Osawa; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2016-08-26       Impact factor: 2.626
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.